Cargando…
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented effort toward the development of an effective and safe vaccine. Aided by extensive research efforts into characterizing and developing countermeasures towards prior coronavirus ep...
Autores principales: | Batty, Cole J., Heise, Mark T., Bachelder, Eric M., Ainslie, Kristy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733686/ https://www.ncbi.nlm.nih.gov/pubmed/33316346 http://dx.doi.org/10.1016/j.addr.2020.12.006 |
Ejemplares similares
-
Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases
por: Genito, Christopher J., et al.
Publicado: (2021) -
Nano/microparticle Formulations for Universal Influenza Vaccines
por: Hendy, Dylan A., et al.
Publicado: (2022) -
Micro and nanotechnologies: The little formulations that could
por: Stiepel, Rebeca T., et al.
Publicado: (2022) -
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
por: Enjuanes, Luis, et al.
Publicado: (2008) -
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
por: Gralinski, Lisa E., et al.
Publicado: (2018)